Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00473746 · ClinicalTrials.gov registry record · Phase 1
Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT00473746 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 66 participants.
The verdict
NCT00473746, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activities of abiraterone acetate (also referred to as CB7630) in patients with hormone refractory prostate cancer (HRPC).
Interventions
- DRUG Abiraterone acetate
- DRUG prednisone/prednisolone or dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2006-06 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00473746
The ClinicalTrials.gov registry entry for NCT00473746 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Abiraterone acetate is the first listed.
NCT00473746 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00473746 about?
NCT00473746 is a clinical study titled "Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer". The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activities of abiraterone acetate (also referred to as CB7630) in patients with hormone refractory prostate cancer (HRPC).
What is the current status of trial NCT00473746?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2006-06. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00473746?
The interventions under investigation include: Abiraterone acetate (DRUG), prednisone/prednisolone or dexamethasone (DRUG).
Who is sponsoring clinical trial NCT00473746?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.